Vitura Health (ASX:VIT) - Stock Price, News & Analysis

VIT Stock Overview

Engages in the sale and distribution of medicinal cannabis products in Australia. More details

VIT fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 33.1% below our estimate of its fair value

Risk Analysis

Does not have a meaningful market cap (A$57M)

Significant insider selling over the past 3 months

Profit margins (2.8%) are lower than last year (11.8%)

Vitura Health Limited Competitors

Vita Life Sciences

ASX:VLS

AU$116.0m

ECS Botanics Holdings

ASX:ECS

AU$1.5m

Neuren Pharmaceuticals

ASX:NEU

AU$1.6b

EZZ Life Science Holdings

ASX:EZZ

AU$112.8m

Price History & Performance

Summary of all time highs, changes and price drops for Vitura Health
Historical stock prices
Current Share Price	AU$0.098
52 Week High	AU$0.32
52 Week Low	AU$0.068
Beta	0.016
11 Month Change	8.89%
3 Month Change	34.25%
1 Year Change	-68.39%
33 Year Change	-53.33%
5 Year Change	-61.57%
Change since IPO	-71.18%

There's No Escaping Vitura Health Limited's (ASX:VIT) Muted Revenues Despite A 33% Share Price Rise

Oct 17

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

Oct 13

Recent updates

There's No Escaping Vitura Health Limited's (ASX:VIT) Muted Revenues Despite A 33% Share Price Rise

Oct 17

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

Oct 13

Vitura Health's (ASX:VIT) Soft Earnings Don't Show The Whole Picture

Sep 07

Vitura Health Limited's (ASX:VIT) 26% Dip In Price Shows Sentiment Is Matching Earnings

Aug 12

Vitura Health Limited (ASX:VIT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Aug 12

The Market Doesn't Like What It Sees From Vitura Health Limited's (ASX:VIT) Earnings Yet As Shares Tumble 43%

Apr 25

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

Apr 11

Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%

Feb 27

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Feb 25

Calculating The Fair Value Of Vitura Health Limited (ASX:VIT)

Dec 13

Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet

Nov 21

Is Now The Time To Put Vitura Health (ASX:VIT) On Your Watchlist?

Nov 01

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Jul 18

Earnings Not Telling The Story For Cronos Australia Limited (ASX:CAU) After Shares Rise 111%

Sep 12

If EPS Growth Is Important To You, Cronos Australia (ASX:CAU) Presents An Opportunity

Sep 05

Shareholder Returns

	VIT	AU Pharmaceuticals	AU Market
7D	0%	-7.2%	-0.3%
1Y	-68.4%	33.2%	18.4%

Return vs Industry: VIT underperformed the Australian Pharmaceuticals industry which returned 34.9% over the past year.

Return vs Market: VIT underperformed the Australian Market which returned 19.7% over the past year.

Price Volatility

Is VIT's price volatile compared to industry and market?
VIT volatility
VIT Average Weekly Movement	11.8%
Pharmaceuticals Industry Average Movement	10.5%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.2%
10% least volatile stocks in AU Market	3.2%

Stable Share Price: VIT has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: VIT's weekly volatility (12%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2018	n/a	n/a	vitura.com.au

Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia. It operates through two segments: Sales and Distribution; and Clinics and Services. The company operates CanView, an online platform that delivers prescribing, dispensing, and medication management solutions for alternative therapies; Doctors on Demand, a premier provider of on-demand virtual healthcare services; BHC, an alternative therapy distributor; CDA Clinics, which provides medicinal consultations and prescription services; and Cannadoc, a medicinal cannabis clinic that offers telehealth consultations.

Vitura Health Limited Fundamentals Summary

How do Vitura Health's earnings and revenue compare to its market cap?
VIT fundamental statistics
Market cap	AU$57.00m
Earnings (TTM)	AU$3.51m
Revenue (TTM)	AU$123.87m

16.2x

P/E Ratio

0.5x

P/S Ratio

Is VIT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VIT income statement (TTM)
Revenue	AU$123.87m
Cost of Revenue	AU$89.65m
Gross Profit	AU$34.22m
Other Expenses	AU$30.71m
Earnings	AU$3.51m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.006
Gross Margin	27.63%
Net Profit Margin	2.84%
Debt/Equity Ratio	13.8%

How did VIT perform over the long term?

See historical performance and comparison

VIT Stock Overview

Rewards

Risk Analysis

Vitura Health Limited Competitors

ASX:VLS

AU$116.0m

ASX:ECS

AU$1.5m

ASX:NEU

AU$1.6b

ASX:EZZ

AU$112.8m

Price History & Performance

Recent News & Updates

Crisci Group and Vitura Health Limited (ASX:VIT) acquired Assets of Releaf Group from Releaf Group Ltd for AUD 6.07 million .

Vitura Health Limited Announces Step Down of Directors

Now 22% undervalued

There's No Escaping Vitura Health Limited's (ASX:VIT) Muted Revenues Despite A 33% Share Price Rise

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

Vitura Health Limited Appoints Stefan Schmidt as Chief Technology Officer

Recent updates

Crisci Group and Vitura Health Limited (ASX:VIT) acquired Assets of Releaf Group from Releaf Group Ltd for AUD 6.07 million .

Vitura Health Limited Announces Step Down of Directors

Now 22% undervalued

There's No Escaping Vitura Health Limited's (ASX:VIT) Muted Revenues Despite A 33% Share Price Rise

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

Vitura Health Limited Appoints Stefan Schmidt as Chief Technology Officer

Vitura Health's (ASX:VIT) Soft Earnings Don't Show The Whole Picture

Vitura Health Limited, Annual General Meeting, Nov 27, 2024

Full year 2024 earnings released: EPS: AU$0.006 (vs AU$0.025 in FY 2023)

Vitura Health Limited Resolves Not to Pay A Dividend in Respect of the Year Ended 30 June 2024

Vitura Health Limited's (ASX:VIT) 26% Dip In Price Shows Sentiment Is Matching Earnings

Vitura Health Limited (ASX:VIT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Less than half of directors are independent

Board Member recently sold AU$1.1m worth of stock

The Market Doesn't Like What It Sees From Vitura Health Limited's (ASX:VIT) Earnings Yet As Shares Tumble 43%

New major risk - Share price stability

Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?

First half 2024 earnings released: EPS: AU$0.006 (vs AU$0.014 in 1H 2023)

Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%

Now 39% undervalued after recent price drop

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Calculating The Fair Value Of Vitura Health Limited (ASX:VIT)

Vitura Health Limited Receives Shareholder Requisition from Elizabeth Sarah Jansen

Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet

Is Now The Time To Put Vitura Health (ASX:VIT) On Your Watchlist?

Vitura Health Limited (ASX:VIT) completed the acquisition of acquire an unknown stake in Doctors on Demand from Yeates Ventures Pty Ltd and Kirsty Garrett.

New minor risk - Shareholder dilution

Vitura Health Limited, Annual General Meeting, Nov 28, 2023

Upcoming dividend of AU$0.01 per share at 2.7% yield

Vitura Health Limited Announces Dividend for the Year Ended 30 June 2023, Payable on or Around, 28 September 2023

New major risk - Earnings quality

New minor risk - Financial data availability

Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching

Insider recently sold AU$2.3m worth of stock

New minor risk - Share price stability

Chief Commercial Officer recently sold AU$5.9m worth of stock

High number of new and inexperienced directors

Cronos Australia Limited Announces Changes to Clinical Operations

High number of new and inexperienced directors

High number of new and inexperienced directors

Cronos Australia Limited Announces Board Changes

High number of new and inexperienced directors

High number of new and inexperienced directors

Cronos Australia Limited Announces Ceases of Benjamin D.N. Jansen as Chief Medical Officer

Cronos Australia Limited Provides Update on Canview 2.0 Platform

Cronos Australia Limited, Annual General Meeting, Nov 29, 2022

Earnings Not Telling The Story For Cronos Australia Limited (ASX:CAU) After Shares Rise 111%

Cronos Australia Limited Appoints Jenelle Frewen and Simone Scovell as Independent Non-Executive Director

If EPS Growth Is Important To You, Cronos Australia (ASX:CAU) Presents An Opportunity

Cronos Australia Limited Announces Dividend for the Year Ended 30 June 2022, Dividend Payment Date Is 11 October 2022

Full year 2022 earnings released: EPS: AU$0.013 (vs AU$0.031 loss in FY 2021)

Cronos Australia Limited to Report Q2, 2022 Results on Jul 27, 2022

Cronos Australia Announces Resignation of Shane Tanner, Chairman and Director

Cronos Australia Limited Announces Resignation of Kurt Thomas Schmidt as Director

First half 2022 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

Cronos Australia Limited (ASX:CAU) completed the acquisition of Cannabis Doctors Australia Pty Ltd.

Cronos Australia Limited (ASX:CAU) entered into Merger implementation agreement to acquire Cannabis Doctors Australia Pty Ltd.

Cronos Australia Limited Announces Launch of Additional Products in Key Asian Markets